Skip to content
Biodatica
Start free

Investigator

Rafael Guerrero-Preston

LIFEGENE-BIOMARKS, INC. · funded by NIMHD, NCI

Companies
2

Resolved onto their grants.

Grants
2

Federal awards on file.

Non-dilutive funding
$1.3M

Summed across those awards.

First award
Sep 20, 2023

Latest Jun 1, 2024.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R42

    Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas

    $366k

    Jun 1, 2024NIMHDLIFEGENE-BIOMARKS, INC.NIH RePORTER · 11238991 (opens the source filing in a new tab)

  2. R44

    Precision DNA methylation test to reduce oral cancer disparities in African Americans patients residing in low-resource settings

    $913k

    Sep 20, 2023NCILIFEGENE-BIOMARKS, INC.NIH RePORTER · 11265166 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources